PriceSensitive

Marvel Biosciences awards 59,693 deferred share units to directors

Market News
TSXV:MRVL
18 November 2026 17:03 (EST)

Source: Stock image generated with AI.

Key Highlights

Marvel Biosciences Corp. (TSXV: MRVL) has awarded 59,693 deferred share units to its three independent directors in place of cash payment for directors’ fees, according to a company press release.

The company said the deferred share units (DSUs) will all vest on November 18, 2027. Once vested, the DSUs are to be settled when a director separates from service from the company, and the DSUs expire 365 days after that separation.

This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.

Marvel said the deemed value of the DSUs was calculated using the volume-weighted average price of its common shares on the TSX Venture Exchange on November 17, 2026, which it reported as $0.13, multiplied by the number of DSUs awarded.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., describes itself as a Calgary-based pre-clinical stage biotechnology company developing MB-204, a fluorinated derivative of the anti-Parkinson’s drug istradefylline.

Read the original press release on Stockhouse.com.

Related News